PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-26.68%
Both companies show declining cash positions (-26.68% vs GNPX's -43.32%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-26.68%
Cash + STI yoy 0.5-0.75x GNPX's -43.32%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-45.50%
Other current assets growth < half of GNPX's -100.00%. David Dodd sees a leaner approach to short-term items.
-27.05%
0.5-0.75x GNPX's -37.80%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-7.44%
≥ 1.5x GNPX's -2.54%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both GNPX and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
12.75%
Less than half of GNPX's -27.29%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-5.69%
≥ 1.5x GNPX's -0.56%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
0.5-0.75x GNPX's -35.05%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
9.15%
Less than half of GNPX's -45.85%. David Dodd sees a more disciplined AP approach or lower volume.
-74.86%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-9.15%
Both GNPX and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
7.01%
Less than half of GNPX's -42.77%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.56%
Higher Total Non-Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Less than half of GNPX's -42.77%. David Dodd sees far fewer liability expansions relative to competitor.
1.65%
Above 1.5x GNPX's 0.25%. Michael Burry suspects heavy new equity expansion or dilution.
-3.34%
0.5-0.75x GNPX's -6.66%. Martin Whitman is wary of weaker retention or lower profitability.
-6.51%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-36.72%
Similar yoy to GNPX's -33.69%. Walter Schloss sees parallel net worth trends.
-25.21%
0.5-0.75x GNPX's -35.05%. Martin Whitman sees underexpansion or possible missed opportunities.
-100.00%
Both GNPX and the company show zero Total Investments Growth.
-11.75%
Less than half of GNPX's 1.17%. David Dodd sees less overall debt expansion vs. competitor.
27.85%
50-75% of GNPX's 43.94%. Bruce Berkowitz notes comparatively lower net debt expansion.